|Tested species reactivity||Bovine, Chicken, Horse, Human, Mouse, Pig, Rat|
|Published species reactivity||Mouse, Not Applicable|
|Host / Isotype||Chicken / IgY|
|Immunogen||Native GFAP purified from bovine spinal cord|
|Contains||0.02% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:50,000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Glial fibrillary acidic protein (GFAP) is a member of the class III intermediate filament protein family. It is heavily, and specifically, expressed in astrocytes and certain other astroglia in the central nervous system, in satellite cells in peripheral ganglia, and in non-myelinating Schwann cells in peripheral nerves. In addition, neural stem cells frequently strongly express GFAP. Antibodies to GFAP are therefore very useful as markers of astrocytic cells. In addition many types of brain tumor, presumably derived from astrocytic cells, heavily express GFAP. GFAP is also found in the lens epithelium, Kupffer cells of the liver, in some cells in salivary tumors and has been reported in erythrocytes.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
The astrocytic response to the dopaminergic denervation of the striatum.
PA1-10004 was used in immunohistochemistry - free floating to characterize how astrocytes respond to dopaminergic denervation of the striatum
|Morales I,Sanchez A,Rodriguez-Sabate C,Rodriguez M||Journal of neurochemistry (139:81)||2016|
Localization and behaviors in null mice suggest that ASIC1 and ASIC2 modulate responses to aversive stimuli.
PA1-10004 was used in immunohistochemistry to study the role of ASIC1 and ASIC2 channels in the defensive response to aversive stimuli
|Price MP,Gong H,Parsons MG,Kundert JR,Reznikov LR,Bernardinelli L,Chaloner K,Buchanan GF,Wemmie JA,Richerson GB,Cassell MD,Welsh MJ||Genes, brain, and behavior (13:179)||2014|
Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke.
PA1-10004 was used in immunohistochemistry to investigate the therapeutic effect of caspase-9 inhibitor on ischemic stroke
|Akpan N,Serrano-Saiz E,Zacharia BE,Otten ML,Ducruet AF,Snipas SJ,Liu W,Velloza J,Cohen G,Sosunov SA,Frey WH,Salvesen GS,Connolly ES,Troy CM||The Journal of neuroscience : the official journal of the Society for Neuroscience (31:8894)||2011|